Developer docs
API playgroundTry for free, no card

Search company profiles

MiNK Therapeutics

Full company profile

uuid000045h

Namestring
MiNK Therapeutics
Legal namestring
MiNK Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2017
Descriptiontext

MiNK Therapeutics is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Founded in 2017 and listed on NASDAQ under ticker INKT, the company operates as an affiliate of Agenus Inc., with corporate headquarters in New York and a research and discovery center in Cambridge, UK. Its lead candidate, agenT-797, is a native (non-engineered) iNKT cell product evaluated across multiple indications including solid tumors (gastroesophageal, gastric, testicular cancers), acute respiratory distress syndrome (ARDS), idiopathic pulmonary fibrosis (IPF), and graft-versus-host disease (GvHD). The pipeline additionally includes engineered products such as MiNK-215 (IL-15 armored FAP-targeting CAR-iNKT for MSS colorectal cancer), PRAME-TCR iNKT (pediatric cancers, partnered with C-Further), and MiNK-413 (BCMA CAR-iNKT for multiple myeloma), supported by two in-house discovery platforms — CARDIS (CAR discovery) and a bispecific iNKT cell engager platform.

The company's proprietary manufacturing process achieves ~99% purity and supports scaling beyond 10,000 doses per year, with dosing demonstrated up to 1×10^9 cells/dose without neurotoxicity or cytokine release syndrome. AgenT-797 is administered without lymphodepletion and can be multi-dosed, and the platform exhibits context-dependent immune modulation — the same unmodified donor batch drives pro-inflammatory TH1 responses in cancer and anti-inflammatory TH2 responses in ARDS without genetic engineering. MiNK is pre-revenue and funds development through equity raises (including a $5.8M private placement in May 2024 and ATM facility drawdowns in 2025), non-dilutive grants (NIAID, C-Further), and shared services via parent Agenus. With 11–50 employees, an enterprise value of roughly $48M, a 2025 net loss of $12.5M, and a $9.5M cash position at end of Q1 2026, the company is dependent on continued capital markets access to fund its Phase 2 programs.

Short descriptiontext

MiNK Therapeutics is a pre-revenue, clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf iNKT cell therapies for solid tumors, ARDS, and other immune-mediated diseases, operating as an affiliate of Agenus Inc. on NASDAQ (INKT).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLexington, United States
HQ citystring
Lexington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
allogeneic cell therapy, iNKT cell therapy, clinical-stage biopharmaceutical, cancer immunotherapy, cell therapy platform
Industry3 codes
PRIMARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cell Therapy Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Clinical-stage biopharmaceutical development
TypeLicensing Royalties
Description

MiNK Therapeutics is a pre-revenue clinical-stage company developing allogeneic iNKT cell therapies. Revenue generation is expected through potential future product sales following regulatory approval, as well as partnership and licensing revenues from collaborations. Current collaborations (C-Further) include non-dilutive funding and downstream commercial revenue participation.

marketscreener.com
2Partnership and collaboration revenues
TypeLicensing Royalties
Description

Non-dilutive funding from collaborations (C-Further: ~$1.1 million for pediatric cancer program) plus double-digit share of downstream commercial revenues from PRAME-targeted iNKT cell therapy. Additional collaboration with Agenus on combination therapy programs.

benzinga.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

MiNK Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf allogeneic invariant Natural Killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Its lead product candidate agenT-797 is being evaluated in Phase 2 trials across solid tumors (gastroesophageal, testicular, gastric cancer), acute lung injury/ARDS, idiopathic pulmonary fibrosis, and graft-versus-host disease. The pipeline also includes engineered CAR-iNKT candidates (MiNK-215 for MSS colorectal cancer, MiNK-413 for multiple myeloma) and a PRAME-targeted TCR-iNKT therapy for pediatric cancers, supported by proprietary CARDIS CAR discovery and bispecific iNKT engager platforms.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 77% disease control rate in PD-1 refractory gastroesophageal adenocarcinoma (Phase II)
+6 more records
Product overview1 text field

MiNK Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapies. The company's lead product agenT-797 is being advanced across multiple indications including solid tumors (gastroesophageal, gastric, testicular cancer), acute lung injury/ARDS, and idiopathic pulmonary fibrosis. The pipeline includes engineered products like MiNK-215 (FAP-targeting CAR-iNKT for colorectal cancer), PRAME-TCR iNKT (pediatric cancers), and MiNK-413 (BCMA CAR-iNKT for multiple myeloma). The company operates two technology platforms: CARDISTM for CAR discovery and a Bispecific iNKT Cell Engager Platform.agenT-797 is also being evaluated in combination with checkpoint inhibitors (botensilimab/balstilimab) for refractory gastroesophageal cancer.

Product and service5 records
1agenT-797
CategoryAllogeneic Cell Therapy
Description

Off-the-shelf allogeneic invariant Natural Killer T (iNKT) cell therapy evaluated across solid tumors (gastroesophageal, testicular, gastric cancer), acute lung injury/ARDS, and idiopathic pulmonary fibrosis. Demonstrates context-dependent immune responses — pro-inflammatory TH1 activation in cancer and anti-inflammatory TH2 in ARDS — from the same unmodified donor batch.

2MiNK-215
CategoryEngineered CAR-iNKT Cell Therapy
Description

IL-15 armored FAP-targeting CAR iNKT cell therapy for solid tumors, being developed for treatment-refractory MSS colorectal cancer liver metastasis. Combines CAR targeting of fibroblast activation protein (FAP) with IL-15 armoring for enhanced persistence and anti-tumor activity.

3MiNK-413
CategoryEngineered CAR-iNKT Cell Therapy
Description

Next-generation armored BCMA CAR iNKT product candidate for multiple myeloma, featuring an armored design for enhanced therapeutic potential.

4PRAME-TCR iNKT Cell Therapy
CategoryEngineered TCR-iNKT Cell Therapy
Description

PRAME-targeted TCR-engineered iNKT cell therapy developed for pediatric cancers including sarcomas, AML, and medulloblastoma, in collaboration with the C-Further consortium and University of Southampton.

5agenT-797 + Botensilimab + Balstilimab Combination
CategoryCombination Cell Therapy Regimen
Description

Combination regimen evaluating agenT-797 with botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) for PD-1 refractory gastroesophageal adenocarcinoma, evaluated at Memorial Sloan Kettering Cancer Center.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1First Lviv Territorial Medical Union
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-14
Description

Clinical trial partnership for Phase 2 randomized trial (C-1300-02) evaluating agenT-797 in patients with severe acute lung injury meeting Global ARDS criteria. The first patient was dosed at this site in Lviv, Ukraine, in collaboration with UNBROKEN Ukraine, with authorization from Ukraine's Ministry of Health.

stocktitan.net
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-14
Description

Partnership with UNBROKEN Ukraine for the Phase 2 ARDS trial (C-1300-02) of agenT-797 in acute lung injury. UNBROKEN Ukraine works in collaboration with First Lviv Territorial Medical Union, providing clinical trial support and authorization from Ukraine's Ministry of Health for the randomized Phase 2 study.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-17
Description

Collaboration on combination therapy combining agenT-797 (MiNK's allo-iNKT cell therapy) with botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) from Agenus. Phase 2 trial at Memorial Sloan Kettering Cancer Center in PD-1 refractory gastroesophageal adenocarcinoma showed 77% disease control rate. Both companies presented data at AACR 2026. Agenus is preparing to file for approval of the combination in colorectal cancer.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-10
Description

International pediatric oncology therapeutics consortium backed by Cancer Research Horizons, LifeArc, and Great Ormond Street Hospital Charity. MiNK received approximately $1.1 million in non-dilutive funding for IND-enabling development of a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers (sarcomas, AML, medulloblastoma). MiNK eligible for a double-digit share of downstream commercial revenues. Investigators at University of Southampton conduct preclinical studies. This is one of C-Further's first two therapeutic programs (CF-033).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-10
Description

Scientific collaborator with MiNK and C-Further for the PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers. Investigators at the University of Southampton conduct independent preclinical studies across pediatric cancer models (sarcomas, AML, medulloblastoma) to evaluate anti-tumor activity and safety and to nominate a lead clinical candidate for first-in-human studies in children.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-06-02
Description

NIAID grant collaboration with the University of Wisconsin to advance allogeneic iNKT cell therapy for the prevention of graft-versus-host disease (GvHD) in stem cell transplant patients. NIAID (National Institute of Allergy and Infectious Diseases) funding supports research into immune regulation to improve transplant outcomes.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight16 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing off-the-shelf allogeneic NK cell therapies for cancer, including engineered CAR-NK programs. Closely comparable to MiNK in modality (innate-like cell therapy), off-the-shelf allogeneic positioning, and early clinical stage.

TypeDirect peer
Description

Develops off-the-shelf iPSC-derived NK and T-cell therapies for cancer and immune disorders. Comparable to MiNK in pursuing allogeneic, ready-to-administer cell therapy platforms with engineered and native configurations.

TypeDirect peer
Description

Pioneer in allogeneic CAR-T cell therapy with multiple clinical-stage programs in hematologic malignancies. Directly comparable to MiNK in allogeneic cell therapy modality, though focused on CAR-T rather than iNKT.

TypeDirect peer
Description

Develops off-the-shelf allogeneic T-cell and CAR-T therapies, including tabelecleucel for post-transplant lymphoproliferative disease. Comparable to MiNK in allogeneic cell therapy modality and use of unmodified and engineered donor-derived T cells.

TypeDirect peer
Description

Clinical-stage gene editing company developing allogeneic CAR-T therapies using its ARCUS platform. Comparable to MiNK in allogeneic CAR-T development for oncology with an off-the-shelf manufacturing approach.

TypeDirect peer
Description

Develops off-the-shelf allogeneic iPSC-derived NK and T-cell therapies, including CAR-engineered variants. Comparable to MiNK in pursuing engineered allogeneic cell therapy products with a manufacturing-driven platform model.

TypeEmerging player
Description

Clinical-stage biotech developing allogeneic CAR-T cell therapies using CRISPR genome editing. Comparable to MiNK in allogeneic CAR-T modality, with a similar early-clinical profile.

TypeEmerging player
Description

Commercial-stage cell therapy company developing engineered TCR-T therapies for solid tumors. Comparable to MiNK in cell therapy for solid tumors with an engineered receptor (TCR or CAR) approach, though autologous rather than allogeneic.

TypeBroad incumbent
Description

Parent company of MiNK and a clinical-stage immuno-oncology company with Fc-enhanced checkpoint antibodies (botensilimab, balstilimab) and bispecific antibody platforms. Comparable to MiNK as the combination partner and shared-CMC/infrastructure provider underpinning MiNK's combination programs.

TypeBroad incumbent
Description

Commercial-stage cell therapy company leading in tumor-infiltrating lymphocyte (TIL) therapy for solid tumors. Comparable to MiNK as an established cell therapy competitor in solid tumor indications where MiNK is positioning agenT-797 and MiNK-215.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MiNK Therapeutics

Cell Therapy Biopharmaceuticalsminktherapeutics.com

MiNK Therapeutics is a pre-revenue, clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf iNKT cell therapies for solid tumors, ARDS, and other immune-mediated diseases, operating as an affiliate of Agenus Inc. on NASDAQ (INKT).

What MiNK Therapeutics does

MiNK Therapeutics is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Founded in 2017 and listed on NASDAQ under ticker INKT, the company operates as an affiliate of Agenus Inc., with corporate headquarters in New York and a research and discovery center in Cambridge, UK. Its lead candidate, agenT-797, is a native (non-engineered) iNKT cell product evaluated across multiple indications including solid tumors (gastroesophageal, gastric, testicular cancers), acute respiratory distress syndrome (ARDS), idiopathic pulmonary fibrosis (IPF), and graft-versus-host disease (GvHD). The pipeline additionally includes engineered products such as MiNK-215 (IL-15 armored FAP-targeting CAR-iNKT for MSS colorectal cancer), PRAME-TCR iNKT (pediatric cancers, partnered with C-Further), and MiNK-413 (BCMA CAR-iNKT for multiple myeloma), supported by two in-house discovery platforms — CARDIS (CAR discovery) and a bispecific iNKT cell engager platform.

The company's proprietary manufacturing process achieves ~99% purity and supports scaling beyond 10,000 doses per year, with dosing demonstrated up to 1×10^9 cells/dose without neurotoxicity or cytokine release syndrome. AgenT-797 is administered without lymphodepletion and can be multi-dosed, and the platform exhibits context-dependent immune modulation — the same unmodified donor batch drives pro-inflammatory TH1 responses in cancer and anti-inflammatory TH2 responses in ARDS without genetic engineering. MiNK is pre-revenue and funds development through equity raises (including a $5.8M private placement in May 2024 and ATM facility drawdowns in 2025), non-dilutive grants (NIAID, C-Further), and shared services via parent Agenus. With 11–50 employees, an enterprise value of roughly $48M, a 2025 net loss of $12.5M, and a $9.5M cash position at end of Q1 2026, the company is dependent on continued capital markets access to fund its Phase 2 programs.

MiNK Therapeutics firmographics

Firmographics
Name
MiNK Therapeutics
Legal name
MiNK Therapeutics, Inc.
Website
https://minktherapeutics.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
MiNK Therapeutics is a pre-revenue, clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf iNKT cell therapies for solid tumors, ARDS, and other immune-mediated diseases, operating as an affiliate of Agenus Inc. on NASDAQ (INKT).
Ownership category
akta.pro rank

MiNK Therapeutics industry classification

Industry
Product category
Cell Therapy Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)

Keywords

  • Allogeneic cell therapy
  • INKT cell therapy
  • Clinical-stage biopharmaceutical
  • Cancer immunotherapy
  • Cell therapy platform

Where MiNK Therapeutics is headquartered

Location

Headquarters

HQ city
Lexington
HQ country
United States
HQ region
North America

Offices3 records

Markets served

MiNK Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Clinical-stage biopharmaceutical development: MiNK Therapeutics is a pre-revenue clinical-stage company developing allogeneic iNKT cell therapies. Revenue generation is expected through potential future product sales following regulatory approval, as well as partnership and licensing revenues from collaborations. Current collaborations (C-Further) include non-dilutive funding and downstream commercial revenue participation.
  2. Partnership and collaboration revenues: Non-dilutive funding from collaborations (C-Further: ~$1.1 million for pediatric cancer program) plus double-digit share of downstream commercial revenues from PRAME-targeted iNKT cell therapy. Additional collaboration with Agenus on combination therapy programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

MiNK Therapeutics product offering

Product offering

Core offering

MiNK Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf allogeneic invariant Natural Killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Its lead product candidate agenT-797 is being evaluated in Phase 2 trials across solid tumors (gastroesophageal, testicular, gastric cancer), acute lung injury/ARDS, idiopathic pulmonary fibrosis, and graft-versus-host disease. The pipeline also includes engineered CAR-iNKT candidates (MiNK-215 for MSS colorectal cancer, MiNK-413 for multiple myeloma) and a PRAME-targeted TCR-iNKT therapy for pediatric cancers, supported by proprietary CARDIS CAR discovery and bispecific iNKT engager platforms.

Product overview

MiNK Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapies. The company's lead product agenT-797 is being advanced across multiple indications including solid tumors (gastroesophageal, gastric, testicular cancer), acute lung injury/ARDS, and idiopathic pulmonary fibrosis. The pipeline includes engineered products like MiNK-215 (FAP-targeting CAR-iNKT for colorectal cancer), PRAME-TCR iNKT (pediatric cancers), and MiNK-413 (BCMA CAR-iNKT for multiple myeloma). The company operates two technology platforms: CARDISTM for CAR discovery and a Bispecific iNKT Cell Engager Platform.agenT-797 is also being evaluated in combination with checkpoint inhibitors (botensilimab/balstilimab) for refractory gastroesophageal cancer.

Differentiator

Problem solved

Functional benefit

Products and services

  • agenT-797 Off-the-shelf allogeneic invariant Natural Killer T (iNKT) cell therapy evaluated across solid tumors (gastroesophageal, testicular, gastric cancer), acute lung injury/ARDS, and idiopathic pulmonary fibrosis. Demonstrates context-dependent immune responses — pro-inflammatory TH1 activation in cancer and anti-inflammatory TH2 in ARDS — from the same unmodified donor batch.
  • MiNK-215 IL-15 armored FAP-targeting CAR iNKT cell therapy for solid tumors, being developed for treatment-refractory MSS colorectal cancer liver metastasis. Combines CAR targeting of fibroblast activation protein (FAP) with IL-15 armoring for enhanced persistence and anti-tumor activity.
  • MiNK-413 Next-generation armored BCMA CAR iNKT product candidate for multiple myeloma, featuring an armored design for enhanced therapeutic potential.
  • PRAME-TCR iNKT Cell Therapy PRAME-targeted TCR-engineered iNKT cell therapy developed for pediatric cancers including sarcomas, AML, and medulloblastoma, in collaboration with the C-Further consortium and University of Southampton.
  • agenT-797 + Botensilimab + Balstilimab Combination Combination regimen evaluating agenT-797 with botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) for PD-1 refractory gastroesophageal adenocarcinoma, evaluated at Memorial Sloan Kettering Cancer Center.

Quantifiable outcome

  • 77% disease control rate in PD-1 refractory gastroesophageal adenocarcinoma (Phase II)
  • +6 more outcomes

Companies that use MiNK Therapeutics

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

MiNK Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

MiNK Therapeutics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • First Lviv Territorial Medical UnioncoreStrategic or Co-development Partner · 14 May 2026Clinical trial partnership for Phase 2 randomized trial (C-1300-02) evaluating agenT-797 in patients with severe acute lung injury meeting Global ARDS criteria. The first patient was dosed at this site in Lviv, Ukraine, in collaboration with UNBROKEN Ukraine, with authorization from Ukraine's Ministry of Health.
  • UNBROKEN UkrainecoreStrategic or Co-development Partner · 14 May 2026Partnership with UNBROKEN Ukraine for the Phase 2 ARDS trial (C-1300-02) of agenT-797 in acute lung injury. UNBROKEN Ukraine works in collaboration with First Lviv Territorial Medical Union, providing clinical trial support and authorization from Ukraine's Ministry of Health for the randomized Phase 2 study.
  • Agenus Inc.coreStrategic or Co-development Partner · 17 April 2026Collaboration on combination therapy combining agenT-797 (MiNK's allo-iNKT cell therapy) with botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) from Agenus. Phase 2 trial at Memorial Sloan Kettering Cancer Center in PD-1 refractory gastroesophageal adenocarcinoma showed 77% disease control rate. Both companies presented data at AACR 2026. Agenus is preparing to file for approval of the combination in colorectal cancer.
  • C-FurthercoreStrategic or Co-development Partner · 10 March 2026International pediatric oncology therapeutics consortium backed by Cancer Research Horizons, LifeArc, and Great Ormond Street Hospital Charity. MiNK received approximately $1.1 million in non-dilutive funding for IND-enabling development of a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers (sarcomas, AML, medulloblastoma). MiNK eligible for a double-digit share of downstream commercial revenues. Investigators at University of Southampton conduct preclinical studies. This is one of C-Further's first two therapeutic programs (CF-033).
  • University of SouthamptoncoreStrategic or Co-development Partner · 10 March 2026Scientific collaborator with MiNK and C-Further for the PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers. Investigators at the University of Southampton conduct independent preclinical studies across pediatric cancer models (sarcomas, AML, medulloblastoma) to evaluate anti-tumor activity and safety and to nominate a lead clinical candidate for first-in-human studies in children.
  • University of WisconsinminorStrategic or Co-development Partner · 2 June 2025NIAID grant collaboration with the University of Wisconsin to advance allogeneic iNKT cell therapy for the prevention of graft-versus-host disease (GvHD) in stem cell transplant patients. NIAID (National Institute of Allergy and Infectious Diseases) funding supports research into immune regulation to improve transplant outcomes.

Scale indicators14 records

Recent moves6 records

Expansion highlights16 records

MiNK Therapeutics competitors and assessment

Company assessment

Direct peers

  • Nkarta Therapeutics: Clinical-stage biotech developing off-the-shelf allogeneic NK cell therapies for cancer, including engineered CAR-NK programs. Closely comparable to MiNK in modality (innate-like cell therapy), off-the-shelf allogeneic positioning, and early clinical stage.
  • Fate Therapeutics: Develops off-the-shelf iPSC-derived NK and T-cell therapies for cancer and immune disorders. Comparable to MiNK in pursuing allogeneic, ready-to-administer cell therapy platforms with engineered and native configurations.
  • Allogene Therapeutics: Pioneer in allogeneic CAR-T cell therapy with multiple clinical-stage programs in hematologic malignancies. Directly comparable to MiNK in allogeneic cell therapy modality, though focused on CAR-T rather than iNKT.
  • Atara Biotherapeutics: Develops off-the-shelf allogeneic T-cell and CAR-T therapies, including tabelecleucel for post-transplant lymphoproliferative disease. Comparable to MiNK in allogeneic cell therapy modality and use of unmodified and engineered donor-derived T cells.
  • Precision BioSciences: Clinical-stage gene editing company developing allogeneic CAR-T therapies using its ARCUS platform. Comparable to MiNK in allogeneic CAR-T development for oncology with an off-the-shelf manufacturing approach.
  • Century Therapeutics: Develops off-the-shelf allogeneic iPSC-derived NK and T-cell therapies, including CAR-engineered variants. Comparable to MiNK in pursuing engineered allogeneic cell therapy products with a manufacturing-driven platform model.

Emerging players

  • Caribou Biosciences: Clinical-stage biotech developing allogeneic CAR-T cell therapies using CRISPR genome editing. Comparable to MiNK in allogeneic CAR-T modality, with a similar early-clinical profile.
  • Adaptimmune Therapeutics: Commercial-stage cell therapy company developing engineered TCR-T therapies for solid tumors. Comparable to MiNK in cell therapy for solid tumors with an engineered receptor (TCR or CAR) approach, though autologous rather than allogeneic.

Broad incumbents

  • Agenus Inc. Parent company of MiNK and a clinical-stage immuno-oncology company with Fc-enhanced checkpoint antibodies (botensilimab, balstilimab) and bispecific antibody platforms. Comparable to MiNK as the combination partner and shared-CMC/infrastructure provider underpinning MiNK's combination programs.
  • Iovance Biotherapeutics: Commercial-stage cell therapy company leading in tumor-infiltrating lymphocyte (TIL) therapy for solid tumors. Comparable to MiNK as an established cell therapy competitor in solid tumor indications where MiNK is positioning agenT-797 and MiNK-215.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

MiNK Therapeutics social profiles

Digital presence

MiNK Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MiNK Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

MiNK Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MiNK Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MiNK Therapeutics

What does MiNK Therapeutics do?

MiNK Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf allogeneic invariant Natural Killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Its lead product candidate agenT-797 is being evaluated in Phase 2 trials across solid tumors (gastroesophageal, testicular, gastric cancer), acute lung injury/ARDS, idiopathic pulmonary fibrosis, and graft-versus-host disease. The pipeline also includes engineered CAR-iNKT candidates (MiNK-215 for MSS colorectal cancer, MiNK-413 for multiple myeloma) and a PRAME-targeted TCR-iNKT therapy for pediatric cancers, supported by proprietary CARDIS CAR discovery and bispecific iNKT engager platforms.

Is MiNK Therapeutics a public or private company?

MiNK Therapeutics is a public company. It is classified as public and is currently operating.

When was MiNK Therapeutics founded?

MiNK Therapeutics was founded in 2017. It employs 11 to 50 people.

Where is MiNK Therapeutics based?

MiNK Therapeutics is headquartered in Lexington, United States, in the North America region.

How does MiNK Therapeutics make money?

Two revenue lines are on record. Clinical-stage biopharmaceutical development is the primary driver. The others are partnership and collaboration revenues.

Who are MiNK Therapeutics's main competitors?

Direct peers on record are Nkarta Therapeutics, Fate Therapeutics, Allogene Therapeutics, Atara Biotherapeutics, Precision BioSciences and Century Therapeutics. Emerging players are Caribou Biosciences and Adaptimmune Therapeutics. Broad incumbents are Agenus Inc. and Iovance Biotherapeutics.

Does MiNK Therapeutics have an API?

No public API is recorded for MiNK Therapeutics.

What industry is MiNK Therapeutics in?

MiNK Therapeutics's product category is Cell Therapy Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAD, NK Cell Therapies, with a secondary code of HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StIs MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Deliver On Growth Plans?MiNK Therapeutics had a cash runway of about 12 months as of September 2026, with US$7.5m cash and US$7.2m annual cash burn. Its burn rate rose 29% year-over-year, and raising another year's cash would dilute shareholders by 15% of market cap.TradingViewMiNK Therapeutics Reports $0.2M in Revenue and $2.6M Q3 Net LossMiNK Therapeutics reported $0.2 million in first pre-commercial product revenue and a $2.6 million net loss for Q3 2026, with net loss per share of $0.50. The company's Phase 2 ARDS trial continues enrolling, with U.S. dosing expected before year-end and an initial readout planned in H2 2027.Seeking AlphaMiNK Therapeutics, Inc. (INKT) Q3 2026 Earnings Call TranscriptMiNK Therapeutics held its Q3 2026 earnings call on November 11, 2026, with CEO Jennifer Buell and CFO Melissa Orilall. The call included forward-looking statements on clinical development, regulatory plans, and cash resources, with the company reporting progress on its randomized trial in critical illness and multiple clinical programs.Quiver QuantitativeMINK THERAPEUTICS ($INKT) Releases Q3 2026 Earnings | INKT Stock NewsMink Therapeutics reported Q3 2026 earnings of -$0.50 per share, beating estimates of -$0.51, but revenue of $200,000 missed estimates of $892,500. Insiders made three sales in the past six months, and 11 institutional investors added shares while 8 reduced positions.The future of tradingMiNK Therapeutics Q3 loss narrows due to lower professional fees and stock compensationMiNK Therapeutics reported a Q3 net loss of $2.6 million, with net loss per share improving 23% year-over-year to $0.50. The company recognized first pre-commercial revenue from its product agenT-797 via named-patient access. It plans to begin US dosing in its ARDS trial before year-end 2026.GlobeNewswireMiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell TherapiesMiNK Therapeutics reported Q3 2026 results, including its first pre-commercial revenue of $0.2 million from agenT-797 named-patient access. The company's randomized ARDS trial is advancing, with U.S. dosing expected before year-end and data in H2 2027. ARPA-H selected its cells for a deployability program with up to $87 million in funding.Stock TitanMiNK Therapeutics Q3 results: first $200K product revenueMiNK Therapeutics reported Q3 2026 results, including its first $200,000 pre-commercial revenue from agenT-797 via named-patient access. The company's randomized ARDS trial is advancing, and ARPA-H selected its cells for a deployability program with up to $87 million in funding. U.S. dosing is expected before year-end.FinancialContent Business PageArticles from MiNK TherapeuticsImmunoScape and MiNK Therapeutics announced a collaboration to discover and develop next-generation TCR therapies against novel targets in solid tumors. The partnership aims to accelerate TCR-based therapies for T cells, iNKT cells, and other modalities, potentially offering new approaches for diverse cancer indications.The future of tradingMiNK Therapeutics Reports Preclinical Data Supporting AgenT-797 Combination in Colorectal CancerMiNK Therapeutics announced preclinical data on its AgenT-797 iNKT cell therapy, showing tumor-cell killing in a colorectal cancer liver-metastasis model resistant to botensilimab and balstilimab alone. The findings support an ongoing Phase 2 combination trial in previously treated microsatellite-stable colorectal cancer with liver metastases.American Banking and Market NewsMiNK Therapeutics (NASDAQ:INKT) Now Covered by Analysts at HC WainwrightHC Wainwright initiated coverage on MiNK Therapeutics with a buy rating and a $38 price target. The stock opened at $10.76, and the company's average analyst rating is Hold with a $44 target. CEO Jennifer Buell sold 6,938 shares for $73,265.28.